Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Total Non-current Liabilities
All obligations due after more than one year.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 51.3% from a year ago
Total non-current liabilities stood at $406K at the end of Q1 FY2026, down 51.3% from a year earlier and down 24.0% from the prior quarter. Over 3 fiscal years it compounded at -27.0% a year.
Context
- Total non-current liabilities amounted to 0.2% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -51.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 534K USD
- Year-over-year change
- -43.0%
- 4-year CAGR
- -32.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 534K | -43.0% |
| FY2024 | 2024-12-31 | 937K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 1.37M | -47.2% |
| FY2021 | 2021-12-31 | 2.6M | — |
Total Non-current Liabilities vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -51.3% is the 8th highest of 10, against a peer median of -23.8%.
- Total non-current liabilities amounts to 0.2% of total assets for CRVS, versus a peer median of 20.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $262M USD | -17.1% | -17.6% | 28.4% | |
| Jun 2026 | $121.02M USD | -24.5% | -20.8% | 11.1% | |
| Mar 2026 | $100.74M USD | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $55.07M USD | -81.6% | -51.3% | 20.7% | |
| Dec 2025 | €47.75M EUR | -31.0% | -24.8% | 76.2% | |
| Mar 2026 | $28.47M USD | -23.8% | +90.4% | 19.5% | |
| Dec 2025 | $17.74M USD | +3070.2% | +7.6% | 22.7% | |
| Mar 2026 | $8.42M USD | +34.2% | +68.7% | 4.1% | |
| Mar 2026 | $5.39M USD | -76.8% | -68.7% | 1.5% | |
| Mar 2026 | $406K USD | -51.3% | -27.0% | 0.2% | |
| Peer median (excluding CRVS) | — | -23.8% | -17.6% | 20.7% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.46M | 13.16M | 12.62M | 8.74M | 4.58M |
| Short-term Investments | 5.99M | 29.14M | 14.53M | 43.22M | 52.17M |
| Net Receivables | 539K | 633K | 63K | 216K | 374K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 128K | 102K | 220K | 548K | 318K |
| Total Current Assets | 71.31M | 43.66M | 27.96M | 54.41M | 58.21M |
| Property, Plant & Equipment (Net) | 3.64M | 2.57M | 1.39M | 1.33M | 1.06M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 34.27M | 21.88M | 16.12M | 12.54M | 10.99M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 236K | 129K | 89K | 632K | 855K |
| Total Non-current Assets | 38.14M | 24.58M | 17.6M | 14.5M | 12.91M |
| Total Assets | 109.46M | 68.24M | 45.55M | 68.91M | 71.12M |
| Account Payables | 1.57M | 1.98M | 1.53M | 2.58M | 2.49M |
| Short-term Debt | 0 | 0 | 0 | 0 | 403K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.97M | 1.27M | 929K | 30.02M | 5.85M |
| Total Current Liabilities | 9.69M | 10.75M | 6.87M | 35.4M | 9.38M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 2.6M | 1.37M | 0 | 937K | 534K |
| Total Liabilities | 12.29M | 12.13M | 6.87M | 36.34M | 9.91M |
| Common Stock | 5K | 5K | 5K | 7K | 7K |
| Retained Earnings | (266.38M) | (307.69M) | (334.72M) | (397.01M) | (412.29M) |
| Accumulated OCI | 1.87M | (563K) | (967K) | (1.29M) | (896K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 97.16M | 56.12M | 38.68M | 32.57M | 61.21M |
| Total Debt | 3.65M | 2.6M | 1.37M | 1.12M | 937K |
| Net Debt | (59.81M) | (10.56M) | (11.25M) | (7.62M) | (3.64M) |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.